Fresenius Kabi Pharmaceuticals (APCVZ)

[ChangeDirector]

This went up today, awesome, screw the shorts trying to profit from other people's misery.

Sayonara APCVZ:

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-34172

Fresenius Kabi Pharmaceuticals Holding, Inc.

NASDAQ Capital Market

(Exact name of Issuer as specified in its charter and name of Exchange where security is listed and/or registered)

Else-Kroener-Strasse 1 / 61352 Bad Homburg v.d.H. Germany / [phone]

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Contingent Value Rights

(Description of class of securities)

Please place and X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:



¨ 17 CFR 240.12d2-2(a)(1)



¨ 17 CFR 240.12d2-2(a)(2)



¨ 17 CFR 240.12d2-2(a)(3)



¨ 17 CFR 240.12d2-2(a)(4)



¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. (1)



x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Fresenius Kabi Pharmaceuticals Holding, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.




March 4, 2011
By: /s/ Richard J. Tajak
Executive Vice President and Chief Financial Officer

Date Richard J. Tajak Title




(1) Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.





SEC 1654 (03-06)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.